Amylyx Pharmaceuticals, Inc. Financing Cash Flow
Amylyx Pharmaceuticals, Inc. (AMLX) reported Financing Cash Flow of $4.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.48M.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.22M, a 95.10% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$208.00K, a 289.09% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $191.61M, a 239407.50% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $257.03M, a 73758.91% increase from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $348.00K, a 90.18% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $3.54M, a 99.18% decline from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $431.79M, a 172.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.70M 10-Q · filed 2026-08-06 | $4.49M derived: sum of 3 quarters · filed 2026-08-06 | $196.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.22M 10-Q · filed 2026-05-07 | $3.01M derived: sum of 2 quarters · filed 2026-05-07 | $194.62M derived: sum of 3 quarters · filed 2026-05-07 | $194.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $191.40M derived: sum of 2 quarters · filed 2026-03-03 | $191.37M derived: sum of 3 quarters · filed 2026-08-06 | $257.03M 10-K · filed 2026-03-03 |
| 2025-09-30 | $191.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $191.57M derived: sum of 2 quarters · filed 2026-08-06 | $257.24M 10-Q · filed 2025-11-06 | $257.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $65.63M 10-Q · filed 2026-08-06 | $65.74M derived: sum of 3 quarters · filed 2026-08-06 | $65.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $65.66M 10-Q · filed 2026-05-07 | $65.77M derived: sum of 2 quarters · filed 2026-05-07 | $65.85M derived: sum of 3 quarters · filed 2026-05-07 | $65.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $190.00K derived: sum of 2 quarters · filed 2026-03-03 | $217.00K derived: sum of 3 quarters · filed 2026-03-03 | $348.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $107.00K derived: sum of 2 quarters · filed 2025-11-06 | $238.00K 10-Q · filed 2025-11-06 | $468.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $158.00K 10-Q · filed 2025-08-07 | $388.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.28M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $131.00K 10-Q · filed 2025-05-08 | $361.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.25M derived: sum of 3 quarters · filed 2025-05-08 | $2.63M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.12M derived: sum of 2 quarters · filed 2025-03-04 | $2.50M derived: sum of 3 quarters · filed 2025-03-04 | $3.54M 10-K · filed 2025-03-04 |
| 2023-09-30 | $889.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.27M derived: sum of 2 quarters · filed 2024-11-07 | $3.31M 10-Q · filed 2024-11-07 | $235.47M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.42M 10-Q · filed 2024-08-08 | $234.59M derived: sum of 3 quarters · filed 2024-08-08 | $234.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-09 | $233.20M derived: sum of 2 quarters · filed 2024-05-09 | $233.20M derived: sum of 3 quarters · filed 2024-05-09 | $232.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $232.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $232.16M derived: sum of 2 quarters · filed 2024-02-22 | $231.33M derived: sum of 3 quarters · filed 2024-02-22 | $431.79M 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$828.00K derived: sum of 2 quarters · filed 2023-11-09 | $199.63M 10-Q · filed 2023-11-09 | $198.56M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$828.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $199.63M 10-Q · filed 2023-08-10 | $198.56M derived: sum of 3 quarters · filed 2024-02-22 | $330.21M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $200.46M 10-Q · filed 2023-05-11 | $199.39M derived: sum of 2 quarters · filed 2024-02-22 | $331.04M derived: sum of 3 quarters · filed 2024-02-22 | $333.03M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $130.59M derived: sum of 2 quarters · filed 2024-02-22 | $132.58M derived: sum of 3 quarters · filed 2024-02-22 | $158.51M 10-K · filed 2024-02-22 |
| 2021-09-30 | $131.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $133.64M derived: sum of 2 quarters · filed 2022-11-10 | $159.57M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $27.92M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $25.93M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |